StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project：[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
Zurück
HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 54891Erstellt: 4. November 2026

Quinapril Hydrochloride

QUINAPRIL HCL · ACCUPRIL · Korec · Conan · CI-906 · Acupril · ccupril · ACCUPRO

https://huagongshe.com/de/chemical/54891

Molekülstruktur von Quinapril Hydrochloride

Identifikatoren & physikalische Daten

CAS No.82586-55-8
SummenformelC25H31ClN2O5
Durchschnittliche Molmasse475 g/mol
Monoisotopische Masse474,1921498 g/mol
SMILESCCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O.Cl
InChIKeyIBBLRJGOOANPTQ-JKVLGAQCSA-N
PubChem CID54891
ChEMBLCHEMBL1201011
ChEBICHEBI:8714
EC No.620-479-5
DTXSIDDTXSID3021221

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)95,9
H-Brücken-Donoren3
H-Brücken-Akzeptoren6
Frei drehbare Bindungen10
Schwere Atome33
Formalladung0
Komplexität648
Löslichkeit>71.2 [ug/mL] (The mean of the results at pH 7.4)H2O: >10mg/mL
Human DrugsFDA approved drugs -> Active ingredient
Schmelzpunkt120-130 °C (crystals from ethyl acetatetoluene) and 119-121.5 °C (crystals from acetonitrile)120-130°C
Collision Cross Section203.5 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
Other Experimental PropertiesCrystals from ethyl acetate-toluene ... /with/ specific optical rotation at 23 °C for D (sodium) line = +14.5 deg (c = 1.2 in ethanol). Also reported as white crystalline solid from acetonitrile ... /with/ specific optical rotation at 25 °C for D (sodium) line = +15.4 deg (c = 2 in methanol).White to off-white amorphous powder that is freely soluble in aqueous solvents
Lagerbedingungen2-8°C
Aggregatzustandsolid
Farbewhite
InChIKeyIBBLRJGOOANPTQ-ZKASTLJSNA-N
SMILESN1(C(=O)[C@H](C)N[C@H](C(=O)OCC)CCC2C=CC=CC=2)CC2C(=CC=CC=2)C[C@H]1C(=O)O.Cl |&1:3,6,28,r|
CAS Datenbank82586-55-8(CAS DataBase Reference)

Sicherheit & Vorschriften

GHS-EinstufungWarningH361 (53%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]P203, P280, P318, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 66 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
FDA-AnforderungenThe Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl quinapril hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
Hazard Classes and CategoriesRepr. 2 (53%)
LagerbedingungenStorage: Store at controlled room temp 15-30 °C (59-86 °F). Protect from light.
EntsorgungsverfahrenSRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
WechselwirkungenHyperkalemia may occur with potassium supplements, potassium-sparing agents, & NSAIDs. /ACE inhibitorsfrom table/ /Salt not specified/... ACE inhibitors enhance the efficacy of diuretic drugs. This means that even very small doses of diuretics may substantially improve the antihypertensive efficacy of ACE inhibitors& on the other end of the spectrum, the use of high doses of diuretics together with angiotensin converting enzyme inhibitors may lead to excessive reduction in blood pressure & to /sodium ion/ loss in some patients. /ACE inhibitors/ /Salt not specified/Oligopeptidic drugs such as beta-lactams & angiotensin-converting enzyme inhibitors share the same carriers in humans & animals, which results in possible pharmacokinetic interactions. To model such interactions, the effects of quinapril on cephalexin pharmacokinetics were investigated in rats. Blood cephalexin concns were measured by liquid chromatography, & the data were analyzed by a noncompartmental method & by fitting a bicompartmental model by a nonlinear mixed-effect modeling approach. 5 groups of 8 rats were examined. In the first 3 groups, cephalexin elimination kinetics after intra-arterial admin alone or in combination with quinapril given by the parenteral or the oral route were studied, & the occurrence of a pharmacokinetic interaction was not revealed. The absence of an effect of quinapril on cephalexin elimination after parenteral admin might be explained either by the higher affinity of cephalexin for the renal anionic transport system than that of quinapril or by the much higher concns of cephalexin than those of quinapril. In the last 2 groups, cephalexin was administered by the oral route alone or in combination with quinapril. The mean area under the concn-time curve (AUC) for cephalexin was increased by ca. 30% by coadmin of quinapril (40.1 versus 31.4 mg.hr/liter

Anwendungen & Verwendung

Verwenden

Quinapril hydrochloride has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on renal tubular epithelial cell proliferation in human renal tubular epithelial cells. It has also been used as an ACE inhibitor to evaluate its effects on the expression of angiotensin II (AII) in patient-derived Atheroma samples.

P=0.04). The mean elimination clearance of cephalexin was significantly decreased by quinapril, from 0.81 to 0.64 liter/hr/kg of body weight (P<0.05), probably by competitive inhibition of cephalexin secretion at the tubular level. The mean absorption rate constant of cephalexin was significantly lowered by quinapril (from 0.249 to 0.177 hr-1
P<0.01), without modification of the extent of absorption (89%). This pharmacokinetic interaction could be explained by competitive inhibition of cephalexin active transport by quinapril at the intestinal level. /Salt not specified/
Concurrent use /of other hypotension-producing medications/ with ACE inhibitors may produce additive hypotensive effects. /ACE inhibitors/ /Salt not specified/
For more Interactions (Complete) data for QUINAPRIL HYDROCHLORIDE (16 total), please visit the HSDB record page.
ExpositionspfadePeak plasma concentrations of quinapril occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.
ToxizitätsübersichtThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Quinaprilat, the principle active metabolite of quinapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Quinaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Signs and SymptomsOverdose may lead to severe hypotension. The most common adverse effects observed in controlled clinical trials were dizziness, cough, chest pain, dyspnea, fatigue, and nausea/vomiting.
Human Toxicity Excerpts/HUMAN EXPOSURE STUDIES/ ACE inhibitors should be avoided in 2nd and 3rd trimesters because of severe fetal and neonatal toxicity (oligohydramnios, pulmonary hypoplasia, renal failure, anuria, death)severe, persistent, neonatal hypotension may occur. Structural defects after exposure in 2nd or 3rd trimesters include fetal calvarial hypoplasia and, possibly, renal anomalies. /ACE inhibitorsfrom table/ /Salt not specified//HUMAN EXPOSURE STUDIES/ Angioedema is an infrequent but serious and potentially fatal adverse effect of all the ACE inhibitors. Thus, patients starting treatment with these drugs should be explicitly warned to discontinue their use with the advent of any signs of angioedema. /ACE inhibitors/ /Salt not specified//SIGNS AND SYMPTOMS/ The principal adverse effect of ACE inhibitor overdose is hypotension, although hyperkalemia & renal failure may occur. ... /ACE inhibitors/ /Salt not specified/
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver InjuryDrug Induced Liver Injury Rank (DILIrank 2.0)Quinapril hydrochloridevLess-DILI-concern3Adverse reactionsDOI:10.1016/j.drudis.2016.02.015
Non-Human Toxicity Excerpts/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Quinapril hydrochloride was not carcinogenic in mice or rats when given in doses up to 75 or 100 mg/kg/day (50-60 times the max human daily dose, respectively, on an mg/sq m basis and 3.8-10 times the max human daily dose when based on an mg/sq m basis) for 104 weeks. Female rats given the highest dose level had an increased incidence of mesenteric lymph node hemangiomas and skin/sc lipomas./LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ No teratogenic effects of ACCUPRIL were seen in studies of pregnant rats and rabbits. On a mg/kg basis, the doses used were up to 180 times (in rats) and one time (in rabbits) the maximum recommended human dose. /Salt not specified//LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ There were no adverse effects on fertility or reproduction in rats at doses up to 100 mg/kg/day (60 and 10 times the max daily human dose when based on mg/kg and mg/sq m, respectively). /Salt not specified//GENOTOXICITY/ Neither quinapril nor quinaprilat were mutagenic in the Ames bacterial assay with or without metabolic activation. Quinapril was also negative in the following genetic toxicology studies: in vitro mammalian cell point mutation, sister chromatid exchange in cultured cells, and in an in vivo cytogenetic study with rat bone marrow. /Salt not specified/
Antidote and Emergency Treatment... Following gut decontamination, treatment is primarily supportive to maintain an adequate blood pressure. /ACE Inhibitors/ /Salt not specified/
Toxicity DataLD<sub>50</sub>=1739mg/kg (orally in mice)
Non-Human Toxicity ValuesLD50 in male, female mice, rats (mg/kg): 1739, 1840, 4280, 3541 orally504, 523, 158, 107 i.v. /Salt not specified/
Wassergefährdungsklasse (WGK)2
Zollcode2933492250
RTECS-Nr.NW7176000
ToxizitätFreely sol in aq solvents. LD50 in male, female mice, rats (mg/kg): 1739, 1840, 4280, 3541 orally504, 523, 158, 107 i.v. (Kaplan, 1989)
Sicherheitshinweise (S)22-24/25
Lagerklasse6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Gefahrstoffdaten82586-55-8(Hazardous Substances Data)
GefahrenklasseRepr. 2STOT RE 1